Oncology & Cancer

Novel Amgen virus-vaccine shrinks melanoma tumors

Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test.

Health

Web-based nephrology consults may reduce referrals

(HealthDay)—A system of Web-based consultations (telenephrology) may reduce the number of specialty referrals for patients with chronic kidney disease, according to a study published in the March/April issue of the Annals ...

Medications

AstraZeneca buys US cancer drugs firm

AstraZeneca said on Tuesday that it has agreed to buy US-based cancer drugs company Amplimmune, as the Anglo-Swedish pharmaceuticals group seeks to bolster its flagging pipeline of new products.

Medications

Xgeva approved for rare, non-malignant tumor

(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.

Other

Amgen 4Q profit drops 16 pct. on higher spending

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

page 3 from 4